|
While Zytiga is approved for men who have already been treated with chemotherapy, Nierengarten said more physicians are using the drug before chemotherapy. "Evolving treatments in prostate cancer could leave Provenge behind," he wrote. The analyst maintained an "Underperform" rating on Dendreon shares and cut his price target to $4 per share from $5. SHARE ACTION: Dendreon shares lost 47 cents, or 7 percent, to $6.29 in midday trading. The stock is down 42 percent since May 7, when the Seattle company reported its first-quarter results. Johnson & Johnson shares rose 30 cents to $62.08 and Medivation shares declined 48 cents to $82.20.
Copyright 2012 The Associated
Press. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
News | Sports | Business | Rural Review | Teaching & Learning | Home and Family | Tourism | Obituaries
Community |
Perspectives
|
Law & Courts |
Leisure Time
|
Spiritual Life |
Health & Fitness |
Teen Scene
Calendar
|
Letters to the Editor